Logo image of DFFN

DIFFUSION PHARMACEUTICALS IN (DFFN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DFFN - US2537484048 - Common Stock

4.4 USD
+0.46 (+11.68%)
Last: 8/16/2023, 8:00:02 PM
4.46 USD
+0.06 (+1.36%)
After Hours: 8/16/2023, 8:00:02 PM
Fundamental Rating

2

DFFN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While DFFN has a great health rating, there are worries on its profitability. DFFN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DFFN has reported negative net income.
In the past year DFFN has reported a negative cash flow from operations.
In the past 5 years DFFN always reported negative net income.
In the past 5 years DFFN always reported negative operating cash flow.
DFFN Yearly Net Income VS EBIT VS OCF VS FCFDFFN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

DFFN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DFFN Yearly ROA, ROE, ROICDFFN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DFFN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DFFN Yearly Profit, Operating, Gross MarginsDFFN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

DFFN has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for DFFN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DFFN Yearly Shares OutstandingDFFN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
DFFN Yearly Total Debt VS Total AssetsDFFN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.66, we must say that DFFN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.66, DFFN is doing worse than 82.42% of the companies in the same industry.
DFFN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.66
ROIC/WACCN/A
WACCN/A
DFFN Yearly LT Debt VS Equity VS FCFDFFN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 10.71 indicates that DFFN has no problem at all paying its short term obligations.
The Current ratio of DFFN (10.71) is better than 75.43% of its industry peers.
DFFN has a Quick Ratio of 10.71. This indicates that DFFN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 10.71, DFFN is doing good in the industry, outperforming 75.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.71
Quick Ratio 10.71
DFFN Yearly Current Assets VS Current LiabilitesDFFN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

DFFN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.04%, which is quite impressive.
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DFFN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.80% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.57%
EPS Next 2Y9.39%
EPS Next 3Y21.86%
EPS Next 5Y14.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DFFN Yearly Revenue VS EstimatesDFFN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
DFFN Yearly EPS VS EstimatesDFFN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DFFN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DFFN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DFFN Price Earnings VS Forward Price EarningsDFFN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DFFN Per share dataDFFN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

DFFN's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.39%
EPS Next 3Y21.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DFFN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIFFUSION PHARMACEUTICALS IN

NASDAQ:DFFN (8/16/2023, 8:00:02 PM)

After market: 4.46 +0.06 (+1.36%)

4.4

+0.46 (+11.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14
Earnings (Next)11-13 2023-11-13
Inst Owners0%
Inst Owner Change0%
Ins Owners623.55%
Ins Owner Change0%
Market Cap8.98M
Revenue(TTM)N/A
Net Income(TTM)-13.08M
Analysts82.86
Price Target40.8 (827.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-6.41
EYN/A
EPS(NY)-6.5
Fwd EYN/A
FCF(TTM)-6.79
FCFYN/A
OCF(TTM)-6.79
OCFYN/A
SpS0
BVpS6.97
TBVpS6.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.71
Quick Ratio 10.71
Altman-Z -11.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.61%
EPS Next Y7.57%
EPS Next 2Y9.39%
EPS Next 3Y21.86%
EPS Next 5Y14.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.11%
OCF growth 3YN/A
OCF growth 5YN/A

DIFFUSION PHARMACEUTICALS IN / DFFN FAQ

Can you provide the ChartMill fundamental rating for DIFFUSION PHARMACEUTICALS IN?

ChartMill assigns a fundamental rating of 2 / 10 to DFFN.


Can you provide the valuation status for DIFFUSION PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 1 / 10 to DIFFUSION PHARMACEUTICALS IN (DFFN). This can be considered as Overvalued.


How profitable is DIFFUSION PHARMACEUTICALS IN (DFFN) stock?

DIFFUSION PHARMACEUTICALS IN (DFFN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for DIFFUSION PHARMACEUTICALS IN?

The Earnings per Share (EPS) of DIFFUSION PHARMACEUTICALS IN (DFFN) is expected to grow by 7.57% in the next year.